2014 Big Pharma China Growth: The Winner Is…
This article was originally published in PharmAsia News
Despite turbulence in China, multinational drug makers grew on average by 12% in the year, with sales at some increasing by more than 20%. PharmAsia News has combed through pages of earnings releases to identify the winner and winning strategies, as well as the fastest improvers and laggards.
You may also be interested in...
Which drug candidates represent hope, and which hype? The Scrip team examine the COVID-19 pipeline, lessons from China, and some long term impacts on the sector.
China insists there is no double standard and won’t tolerate any quality issues in its centralized procurement process.
After winning a major procurement contract, BeiGene now may need to find an alternative manufacturing site for Celgene's Abraxane to supply China.